Vancomycin and daptomycin are options for the initial treatment of patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. Treatment options for persistent MRSA bacteremia or bacteremia due to vancomycin-intermediate or vancomycin-resistant strains include daptomycin, ceftaroline, and combination therapies. There is a critical need for high-level evidence from clinical trials to allow optimally informed decisions in the treatment of MRSA bacteremia.
Keywords: Bacteremia; Ceftaroline; Daptomycin; Endocarditis; MRSA; Methicillin; Staphylococcus aureus; Vancomycin.
Copyright © 2020 Elsevier Inc. All rights reserved.